Accelerating randomized clinical trials in Alzheimer's disease using generative machine learning model forecasts of disease progression

Digital twins of trial participants can potentially enhance statistical power, allowing for smaller sample sizes and more efficient trials. These methods were validated retrospectively on three pivotal Phase III clinical trials, demonstrating the potential to streamline clinical development in Alzheimer's disease.